Given the FDA’s decision to initiate the removal of boxed warning labels from hormone therapy products, it may be prescribed ...
As 2026 begins, a slate of high-stakes clinical readouts—from a pivotal study of Novartis’ cardiovascular candidate ...
Orphan Drug Designation applies to approximately 50,000 Patients who predominantly suffer from severe chronic pain due to ...
CK0804, a regulatory T cell therapy, received FDA orphan drug designation for myelofibrosis, supporting rare disease treatment development. Clinical study results showed significant reductions in ...
BioNTech's gotistobart receives FDA orphan drug designation, showing promise in improving survival for patients with squamous ...
As of December 31, 2025, NioCorp had a record consolidated cash balance of $307 million. I believe this fundraising success has also significantly strengthened EXIM's confidence in our ability to ...
Preparing for FDA approval and commercial launch of tividenofusp alfa, Denali’s TransportVehicle™ (TV)-enabled investigational therapy for Hunter ...
Amivantamab combined with FOLFOX or FOLFIRI showed a 51% overall response rate in RAS/BRAF wild-type mCRC patients, with a ...
Early Data Suggests a Trend Toward Improvement in Pain Efficacy SASKATOON, SK, Jan. 8, 2026 /CNW/ – ZYUS Life Sciences ...
The FDA has granted breakthrough therapy designation (BTD) to sevabertinib (Hyrnuo, formerly BAY 2927088) for the first-line ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback